Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study

BACKGROUND: Interleukin (IL)-6 is one of the key cytokines in the pathogenesis of secondary hemophagocytic lymphohistiocytosis (sHLH); however, the efficacy and safety of tocilizumab (TCZ), a monoclonal IL-6 receptor antibody, in patients with sHLH is uncertain. METHODS/RESULTS: This study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ju Yeon, Kim, Miso, Park, Jin Kyun, Lee, Eun Bong, Park, Jun Won, Hong, Junshik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490693/
https://www.ncbi.nlm.nih.gov/pubmed/36131317
http://dx.doi.org/10.1186/s13023-022-02516-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490693/
https://www.ncbi.nlm.nih.gov/pubmed/36131317
http://dx.doi.org/10.1186/s13023-022-02516-1

Ejemplares similares